We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Kymera (KYMR) Rises as Dosing Begins in AD Study on KT-474
Read MoreHide Full Article
Kymera Therapeutics, Inc. (KYMR - Free Report) announced that the first patient had been dosed in the phase II ADVANTA study evaluating KT-474 (SAR444656) for treating atopic dermatitisAD, also known as eczema.
Following the start of patient dosing, Kymera received a milestone payment of $15 million from French pharma giant Sanofi (SNY - Free Report) as both companies collaborated to develop KT-474.
Shares of Kymera gained 7.2% on Dec 7 following the announcement of the news.
Sanofi is conducting the phase II study, which is evaluating the safety and efficacy of KT-474 versus placebo in adult patients with moderate to severe AD.
Kymera’s KT-474, a highly selective, orally bioavailable IRAK4 degrader, is also being developed for the treatment of hidradenitis suppurativa (“HS”).
In October 2023, SNY dosed the first patient in another phase II study evaluating KT-474 for treating HS. KYMR received a milestone payment of $40 million upon dosing of the first patient in the HS study.
Top-line data from both HS and AD studies are expected in the first half of 2025.
Shares of Kymera have lost 5.1% so far this year compared with the industry’s decline of 20%.
Image Source: Zacks Investment Research
Apart from this, Kymera is developing oncology degraders, namely KT-333 and KT-253.
KT-333 is being developed in early-stage studies for the treatment of cutaneous T-cell lymphoma (“CTCL”) and peripheral T-cell lymphoma (“PTCL”).
The FDA granted Fast Track designation to KT-333 for the treatment of both relapsed/refractory CTCL and relapsed/refractory PTCL in the third quarter of 2023.
The company is developing KT-253, a degrader that targets MDM2 in early-stage studies for treating patients with solid tumors and lymphomas.
We note that Kymera’s top line currently comprises collaboration revenues from Sanofi. In the absence of a marketed product, the successful development of its pipeline candidates remains a key focus for the company.
In the past 60 days, estimates for Entrada Therapeutics’ 2023 loss per share have narrowed from $2.07 to 9 cents. Meanwhile, loss per share estimates for 2024 have narrowed from $2.35 to $2.04. Year to date, shares of TRDA have decreased 1.1%.
Earnings of Entrada Therapeutics beat estimates in three of the last four quarters while missing the same on the remaining occasion. TRDA delivered a four-quarter average earnings surprise of 70.68%.
In the past 60 days, estimates for Puma Biotechnology’s 2023 earnings per share have improved from 67 cents to 72 cents. During the same period, earnings per share estimates for 2024 have moved up from 55 cents to 64 cents. Year to date, shares of PBYI have lost 1.2%.
Earnings of Puma Biotechnology beat estimates in three of the last four quarters while missing the same on the remaining occasion. PBYI delivered a four-quarter average earnings surprise of 76.55%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Kymera (KYMR) Rises as Dosing Begins in AD Study on KT-474
Kymera Therapeutics, Inc. (KYMR - Free Report) announced that the first patient had been dosed in the phase II ADVANTA study evaluating KT-474 (SAR444656) for treating atopic dermatitisAD, also known as eczema.
Following the start of patient dosing, Kymera received a milestone payment of $15 million from French pharma giant Sanofi (SNY - Free Report) as both companies collaborated to develop KT-474.
Shares of Kymera gained 7.2% on Dec 7 following the announcement of the news.
Sanofi is conducting the phase II study, which is evaluating the safety and efficacy of KT-474 versus placebo in adult patients with moderate to severe AD.
Kymera’s KT-474, a highly selective, orally bioavailable IRAK4 degrader, is also being developed for the treatment of hidradenitis suppurativa (“HS”).
In October 2023, SNY dosed the first patient in another phase II study evaluating KT-474 for treating HS. KYMR received a milestone payment of $40 million upon dosing of the first patient in the HS study.
Top-line data from both HS and AD studies are expected in the first half of 2025.
Shares of Kymera have lost 5.1% so far this year compared with the industry’s decline of 20%.
Apart from this, Kymera is developing oncology degraders, namely KT-333 and KT-253.
KT-333 is being developed in early-stage studies for the treatment of cutaneous T-cell lymphoma (“CTCL”) and peripheral T-cell lymphoma (“PTCL”).
The FDA granted Fast Track designation to KT-333 for the treatment of both relapsed/refractory CTCL and relapsed/refractory PTCL in the third quarter of 2023.
The company is developing KT-253, a degrader that targets MDM2 in early-stage studies for treating patients with solid tumors and lymphomas.
We note that Kymera’s top line currently comprises collaboration revenues from Sanofi. In the absence of a marketed product, the successful development of its pipeline candidates remains a key focus for the company.
Zacks Rank & Stocks to Consider
Kymera currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the healthcare sector are Entrada Therapeutics, Inc. (TRDA - Free Report) and Puma Biotechnology, Inc. (PBYI - Free Report) , each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Entrada Therapeutics’ 2023 loss per share have narrowed from $2.07 to 9 cents. Meanwhile, loss per share estimates for 2024 have narrowed from $2.35 to $2.04. Year to date, shares of TRDA have decreased 1.1%.
Earnings of Entrada Therapeutics beat estimates in three of the last four quarters while missing the same on the remaining occasion. TRDA delivered a four-quarter average earnings surprise of 70.68%.
In the past 60 days, estimates for Puma Biotechnology’s 2023 earnings per share have improved from 67 cents to 72 cents. During the same period, earnings per share estimates for 2024 have moved up from 55 cents to 64 cents. Year to date, shares of PBYI have lost 1.2%.
Earnings of Puma Biotechnology beat estimates in three of the last four quarters while missing the same on the remaining occasion. PBYI delivered a four-quarter average earnings surprise of 76.55%.